2025 Q3 -tulosraportti
Vain PDF
64 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 300
Myynti
Määrä
18 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 30 457 | - | - | ||
| 5 000 | - | - |
Ylin
0,316VWAP
Alin
0,308VaihtoMäärä
0,2 608 583
VWAP
Ylin
0,316Alin
0,308VaihtoMäärä
0,2 608 583
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.
·1 päivä sittenIs there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
·12.1.what is your stance on the new share issue?8 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetall in75%abstains25%·2 päivää sittenRelatively small - Often some of the underwriters later sell their shares with perhaps up to 10 % discount - and then people get nervous and dump the stock when it goes below the emission price. Usually, it corrects itself after a while. Many years ago - with Karolinska Development, however, it went completely wrong - and the price never recovered after the emission. That's why the discount is so tremendously large on the stock. With with the discount as of today, the risk in the stock is immensely small - see my analysis of the discount in my post yesterday. (I have sold all my ordinary shares, bought subscription rights and am using the entire sale sum and a little more to buy into the emission.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
64 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.·1 päivä sittenIs there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
- ·12.1.what is your stance on the new share issue?8 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetall in75%abstains25%·2 päivää sittenRelatively small - Often some of the underwriters later sell their shares with perhaps up to 10 % discount - and then people get nervous and dump the stock when it goes below the emission price. Usually, it corrects itself after a while. Many years ago - with Karolinska Development, however, it went completely wrong - and the price never recovered after the emission. That's why the discount is so tremendously large on the stock. With with the discount as of today, the risk in the stock is immensely small - see my analysis of the discount in my post yesterday. (I have sold all my ordinary shares, bought subscription rights and am using the entire sale sum and a little more to buy into the emission.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 300
Myynti
Määrä
18 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 30 457 | - | - | ||
| 5 000 | - | - |
Ylin
0,316VWAP
Alin
0,308VaihtoMäärä
0,2 608 583
VWAP
Ylin
0,316Alin
0,308VaihtoMäärä
0,2 608 583
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
64 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.·1 päivä sittenIs there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
- ·12.1.what is your stance on the new share issue?8 ääntä PäättynytLiity Sharevilleen nähdäksesi tuloksetall in75%abstains25%·2 päivää sittenRelatively small - Often some of the underwriters later sell their shares with perhaps up to 10 % discount - and then people get nervous and dump the stock when it goes below the emission price. Usually, it corrects itself after a while. Many years ago - with Karolinska Development, however, it went completely wrong - and the price never recovered after the emission. That's why the discount is so tremendously large on the stock. With with the discount as of today, the risk in the stock is immensely small - see my analysis of the discount in my post yesterday. (I have sold all my ordinary shares, bought subscription rights and am using the entire sale sum and a little more to buy into the emission.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 300
Myynti
Määrä
18 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 30 457 | - | - | ||
| 5 000 | - | - |
Ylin
0,316VWAP
Alin
0,308VaihtoMäärä
0,2 608 583
VWAP
Ylin
0,316Alin
0,308VaihtoMäärä
0,2 608 583
Välittäjätilasto
Dataa ei löytynyt